MELATONIN AS A THERAPEUTIC OPTION FOR ENDOMETRIOSIS: A NARRATIVE REVIEW

In: International Journal of Innovative Technologies in Social Science · 2026 · vol. 1(4(52)) · doi:10.31435/ijitss.4(52).2026.6316 · W7223443387
OA: gold CC0
⚙ AI-generated summary by qwen3.7-flash, 2026-10-26 ⓘ

This narrative review synthesizes preclinical and clinical evidence demonstrating that melatonin reduces endometriosis lesion size and pain through antioxidant and anti-inflammatory mechanisms, though larger trials are needed to confirm its efficacy.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-10-26 · read from full text ⓘ

This narrative review synthesizes preclinical and clinical evidence regarding melatonin as a therapeutic adjunct for endometriosis, focusing on its antioxidant, anti-inflammatory, and antinociceptive properties. Rodent models demonstrate that melatonin reduces lesion volume and weight while modulating oxidative stress markers, matrix metalloproteinases, and angiogenic signaling pathways. Clinical data from two randomized controlled trials indicate significant reductions in chronic pelvic pain scores compared to placebo or baseline measures. The authors note that the current evidence base is limited by small sample sizes, short trial durations, and a heavy reliance on animal models rather than large-scale human studies. This paper is centrally about endometriosis — specifically evaluating melatonin’s potential as a fertility-preserving treatment to address oxidative stress and pain associated with the disease.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Endometriosis is a chronic condition in which conventional hormonal suppression and surgical excision are frequently accompanied by high recurrence and risks to ovarian reserve (Q. Li et al., 2024; Y. Li et al., 2024). Melatonin, a pleiotropic neuroendocrine hormone with antioxidant, anti-inflammatory, and antinociceptive properties, has emerged as an adjunctive candidate that targets the oxidative-inflammatory-angiogenic axis without suppressing reproductive function (Li et al., 2022; Mosher et al., 2019). This narrative review synthesizes the available preclinical and clinical evidence, retrieved through a structured search of PubMed, Scopus, and Web of Science (January 2005–May 2025), examining melatonin's therapeutic role across seven mechanistic domains: lesion size, histological characteristics, oxidative stress, inflammatory modulation, matrix metalloproteinase regulation, angiogenesis, and chronic pelvic pain. Across more than a dozen rodent studies at 10–50 mg/kg/day, melatonin consistently reduced lesion volume and weight, restored superoxide dismutase and catalase activity while lowering malondialdehyde and COX-2, downregulated proMMP-9 and elevated TIMP-1/TIMP-2, and suppressed VEGF/VEGFR-2 signaling (Mosher et al., 2019; Yılmaz et al., 2014). Clinically, two randomized controlled trials — Schwertner et al. (n = 40, 10 mg nightly, 8 weeks) (Schwertner et al., 2013) and Esmaeilzadeh et al. (n = 80) (Esmaeilzadeh et al., 2025) — documented analgesic benefit, with the former reducing daily pain by 39.80% and the latter yielding a VAS change of −1.56 (P < 0.001). Melatonin is therefore a mechanistically distinctive, fertility-preserving adjunctive candidate for endometriosis. However, the evidence base remains weighted toward preclinical rodent models and rests on a small number of short-duration randomized trials. Larger Phase III studies with imaging-based endpoints, dose-finding designs, active-comparator arms, and extended follow-up are required before its clinical role can be considered definitive.
Full text 10,043 characters · extracted from oa-html · click to expand
MELATONIN AS A THERAPEUTIC OPTION FOR ENDOMETRIOSIS: A NARRATIVE REVIEW DOI: https://doi.org/10.31435/ijitss.4(52).2026.6316Keywords: Melatonin, Endometriosis, Oxidative Stress, Chronic Pelvic Pain, Anti-inflammatory AgentsAbstract Endometriosis is a chronic condition in which conventional hormonal suppression and surgical excision are frequently accompanied by high recurrence and risks to ovarian reserve (Q. Li et al., 2024; Y. Li et al., 2024). Melatonin, a pleiotropic neuroendocrine hormone with antioxidant, anti-inflammatory, and antinociceptive properties, has emerged as an adjunctive candidate that targets the oxidative-inflammatory-angiogenic axis without suppressing reproductive function (Li et al., 2022; Mosher et al., 2019). This narrative review synthesizes the available preclinical and clinical evidence, retrieved through a structured search of PubMed, Scopus, and Web of Science (January 2005–May 2025), examining melatonin's therapeutic role across seven mechanistic domains: lesion size, histological characteristics, oxidative stress, inflammatory modulation, matrix metalloproteinase regulation, angiogenesis, and chronic pelvic pain. Across more than a dozen rodent studies at 10–50 mg/kg/day, melatonin consistently reduced lesion volume and weight, restored superoxide dismutase and catalase activity while lowering malondialdehyde and COX-2, downregulated proMMP-9 and elevated TIMP-1/TIMP-2, and suppressed VEGF/VEGFR-2 signaling (Mosher et al., 2019; Yılmaz et al., 2014). Clinically, two randomized controlled trials — Schwertner et al. (n = 40, 10 mg nightly, 8 weeks) (Schwertner et al., 2013) and Esmaeilzadeh et al. (n = 80) (Esmaeilzadeh et al., 2025) — documented analgesic benefit, with the former reducing daily pain by 39.80% and the latter yielding a VAS change of −1.56 (P < 0.001). Melatonin is therefore a mechanistically distinctive, fertility-preserving adjunctive candidate for endometriosis. However, the evidence base remains weighted toward preclinical rodent models and rests on a small number of short-duration randomized trials. Larger Phase III studies with imaging-based endpoints, dose-finding designs, active-comparator arms, and extended follow-up are required before its clinical role can be considered definitive. References Anderson, G. (2019). Endometriosis Pathoetiology and Pathophysiology: Roles of Vitamin A, Estrogen, Immunity, Adipocytes, Gut Microbiome and Melatonergic Pathway on Mitochondria Regulation. BioMolecular Concepts, 10(1), 133–149. https://doi.org/10.1515/bmc-2019-0017 Çetinkaya, N., Attar, R., Yıldırım, G., Fıçıcıoğlu, C., Özkan, F., Yılmaz, B., & Yeşildağlar, N. (2014). The effects of different doses of melatonin treatment on endometrial implants in an oophorectomized rat endometriosis model. https://doi.org/10.1007/s00404-014-3466-3 Chuffa, L. G. de A., Lupi, L. A., Cucielo, M. S., Silveira, H. S., Reiter, R. J., & Seiva, F. R. F. (2019). Melatonin Promotes Uterine and Placental Health: Potential Molecular Mechanisms. International Journal of Molecular Sciences, 21(1), 300–300. https://doi.org/10.3390/ijms21010300 Dymanowska-Dyjak, I., Frankowska, K., Abramiuk, M., & Polak, G. (2024). Oxidative Imbalance in Endometriosis-Related Infertility—The Therapeutic Role of Antioxidants. International Journal of Molecular Sciences, 25(12), 6298–6298. https://doi.org/10.3390/ijms25126298 Esmaeilzadeh, S., Habibolahi, F., Moher, D., Basirat, Z., Gholinia, H., Golsorkhtabaramiri, M., & Mirabi, P. (2025). Melatonin and sleep parameters in infertile women with endometriosis: first results from the triple-blind randomized controlled trial of administration of melatonin in chronic pelvic pain and sleep disturbance. https://doi.org/10.1371/journal.pone.0321635 Esmaeilzadeh, S., Sadrzadeh, A., Moher, D., Sepidarkish, M., Alamolhoda, S. H., & Mirabi, P. (2025). Efficacy of antioxidant supplementation in alleviating endometriosis-related pain: insights from a systematic review and meta-analysis of RCTs. Reproductive Biology and Endocrinology, 23(1), 164–164. https://doi.org/10.1186/s12958-025-01485-x Ferreira, I. de O., Barbon, M., Rosa, J. T. da, Costella, A. P., Brietzke, A. P., & Laste, G. (2024). Melatonin and Gynecologic Disorders: A Literature Review. Journal of Advances in Medicine and Medical Research, 36(2), 143–159. https://doi.org/10.9734/jammr/2024/v36i25375 Harlev, A., Gupta, S., & Agarwal, A. (2015). Targeting oxidative stress to treat endometriosis. https://doi.org/10.1517/14728222.2015.1077226 Khatun, M. S., Islam, Md. A., Islam, T., Islam, M. A., Ishrat, S., Deeba, F., Jahan, N., & Banu, J. (2025). Efficacy of melatonin and letrozole combination therapy compared to letrozole alone in the treatment of symptomatic endometrioma in infertile women. International Journal of Reproduction Contraception Obstetrics and Gynecology, 14(9), 2853–2858. https://doi.org/10.18203/2320-1770.ijrcog20252709 Koç, Ö., Gündüz, B., Topçuoğlu, A., Buğdaycı, G., Yılmaz, F., & Duran, B. (2010). Effects of pinealectomy and melatonin supplementation on endometrial explants in a rat model. https://doi.org/10.1016/j.ejogrb.2010.06.012 Li, Q., Zheng, T., Chen, J., Li, B., Zhang, Q., Yang, S., Shao, J., Guan, W., & Zhang, S. (2024). Exploring melatonin’s multifaceted role in female reproductive health: From follicular development to lactation and its therapeutic potential in obstetric syndromes. https://doi.org/10.1016/j.jare.2024.04.025 Li, Y., Hung, S. W., Xu, Z., Ding, Y., Zhang, T., Tan, Z., Zhang, R., Lin, Y., Song, Y., Wang, Y., & Wang, C. C. (2024). Melatonin Inhibits Endometriosis Growth via Specific Binding and Inhibition of EGFR Phosphorylation. https://doi.org/10.1111/jpi.70022 Li, Y., Hung, S. W., Zhang, R., Man, G. C. W., Zhang, T., Chung, J. P. W., Fang, L., & Wang, C. C. (2022). Melatonin in Endometriosis: Mechanistic Understanding and Clinical Insight. https://doi.org/10.3390/nu14194087 Mosher, A., Tsoulis, M., Lim, J., Tan, C., Agarwal, S. K., Leyland, N., & Foster, W. G. (2019). Melatonin activity and receptor expression in endometrial tissue and endometriosis. https://doi.org/10.1093/humrep/dez082 Ou, Y., Wang, H., Zhou, C., Chen, Y., Lyu, J., Feng, M., & Huang, X. (2025). Endometriosis-associated infertility: Multi-omics insights into pathogenesis and precision therapeutics. Frontiers in Endocrinology, 16, 1613334–1613334. https://doi.org/10.3389/fendo.2025.1613334 Parua, S., Choudhury, G. R., Bhattacharya, S., Hazra, A., Dutta, S., Sengupta, P., & Bhattacharya, K. (2024). Melatonin in Female Fertility: Multifaceted Role From Reproductive Physiology to Therapeutic Potential in Polycystic Ovary Syndrome, Endometriosis, and Ovarian Failure. Chronobiology in Medicine, 6(4), 145–162. https://doi.org/10.33069/cim.2024.0022 Paul, S., Sharma, A. V., Mahapatra, P. D., Bhattacharya, P., Reiter, R. J., & Swarnakar, S. (2008). Role of melatonin in regulating matrix metalloproteinase‐9 via tissue inhibitors of metalloproteinase‐1 during protection against endometriosis. Journal of Pineal Research, 44(4), 439–449. https://doi.org/10.1111/j.1600-079x.2007.00547.x Schwertner, A., Santos, C. C. C. dos, Costa, G. D., Deitos, A., Souza, A. de, Souza, I. C. C. de, Torres, I. L. da S., Cunha‐Filho, J. S., & Caumo, W. (2013). Efficacy of melatonin in the treatment of endometriosis: A phase II, randomized, double-blind, placebo-controlled trial. https://doi.org/10.1016/j.pain.2013.02.025 Söderman, L., Böttiger, Y., Edlund, M., Järnbert‐Pettersson, H., & Marions, L. (2023). Adjuvant use of melatonin for pain management in endometriosis-associated pelvic pain—A randomized double-blinded, placebo-controlled trial. https://doi.org/10.1371/journal.pone.0286182 Tesařík, J., & Tesarik, R. M. (2025). Melatonin in the Treatment of Female Infertility: Update on Biological and Clinical Findings. Biomedicines, 13(10), 2434–2434. https://doi.org/10.3390/biomedicines13102434 Yang, H., Zhou, W., Gu, C., Meng, Y., Shao, J., Li, D., & Li, M. (2018). Pleiotropic roles of melatonin in endometriosis, recurrent spontaneous abortion, and polycystic ovary syndrome. https://doi.org/10.1111/aji.12839 Yeşildağlar, N., Yıldırım, G., YILDIRIM, Ö., Attar, R., Özkan, F., Akkaya, H., & Yılmaz, B. (2016). The effects of melatonin on endometriotic lesions induced by implanting human endometriotic cells in the first SCID-mouse endometriosis-model developed in Turkey. https://doi.org/10.12891/ceog2035.2016 Yıldırım, G., Attar, R., Özkan, F., Kumbak, B., Fıçıcıoğlu, C., & Yeşildağlar, N. (2009). The effects of letrozole and melatonin on surgically induced endometriosis in a rat model: a preliminary study. https://doi.org/10.1016/j.fertnstert.2009.09.021 Yılmaz, B., Kılıç, S., Aksakal, O., Ertaş, İ. E., Tanrisever, G. G., Aksoy, Y., Lortlar, N., Kelekçi, S., & Gungor, T. (2014). Melatonin causes regression of endometriotic implants in rats by modulating angiogenesis, tissue levels of antioxidants and matrix metalloproteinases. https://doi.org/10.1007/s00404-014-3599-4 Zhong, Y., Qiao, X., Huang, X., Li, Y., Wang, R., Liang, J., Liu, T., Bo, W., Lai, H., & Huang, W. (2025). The effects of antioxidant supplementation on pain, oxidative stress markers, and clinical pregnancy rate in women with endometriosis: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Medicine, 12, 1694281–1694281. https://doi.org/10.3389/fmed.2025.1694281 Downloads Published Issue Section License Copyright (c) 2026 Rafał Marciniak, Anna Bociąg, Łukasz Ptach, Konrad Kowalski, Aleksandra Milewska This work is licensed under a Creative Commons Attribution 4.0 International License. All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles. CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (25)

Source provenance

openalex
last seen: 2026-10-28T06:07:52.114647+00:00
License: CC0 · commercial use OK